Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Aurinia Pharmaceuticals

DB:IKAP
Snowflake Description

Exceptional growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IKAP
DB
CA$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Aurinia Pharmaceuticals has significant price volatility in the past 3 months.
IKAP Share Price and Events
7 Day Returns
0%
DB:IKAP
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
134.7%
DB:IKAP
-7.4%
DE Biotechs
-14.2%
DE Market
IKAP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aurinia Pharmaceuticals (IKAP) 0% -5% -28.1% 134.7% 109.2% 255%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • IKAP outperformed the Biotechs industry which returned -7.4% over the past year.
  • IKAP outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
IKAP
Industry
5yr Volatility vs Market

IKAP Value

 Is Aurinia Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aurinia Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aurinia Pharmaceuticals.

DB:IKAP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IKAP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 26.5%) (0%))
1.032
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.032 * 5.44%)
5.23%

Discounted Cash Flow Calculation for DB:IKAP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aurinia Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:IKAP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.23%)
2020 -110.00 Analyst x2 -104.54
2021 -79.33 Analyst x3 -71.65
2022 21.33 Analyst x3 18.31
2023 164.67 Analyst x3 134.32
2024 314.33 Analyst x3 243.66
2025 440.20 Est @ 40.04% 324.28
2026 563.06 Est @ 27.91% 394.20
2027 672.42 Est @ 19.42% 447.38
2028 763.05 Est @ 13.48% 482.47
2029 834.14 Est @ 9.32% 501.23
Present value of next 10 years cash flows $2,369.00
DB:IKAP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $834.14 × (1 + -0.39%) ÷ (5.23% – -0.39%)
$14,796.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $14,796.84 ÷ (1 + 5.23%)10
$8,891.32
DB:IKAP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,369.00 + $8,891.32
$11,260.32
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $11,260.32 / 112.30
$100.27
DB:IKAP Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of TSX:AUP)
1.4
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $100.27 x 1.4
CA$140.39
Non-primary Listing Adjustment Factor 1 share in DB:IKAP represents 0.63789x of TSX:AUP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.63789x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 140.39 x 0.63789
€89.55
Value per share (EUR) From above. €89.55
Current discount Discount to share price of €13.30
= -1 x (€13.30 - €89.55) / €89.55
85.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aurinia Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €13.3 vs Future cash flow value of €89.55
Current Discount Checks
For Aurinia Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aurinia Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aurinia Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aurinia Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aurinia Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IKAP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.33
TSX:AUP Share Price ** TSX (2020-04-08) in CAD CA$20.85
TSX:AUP Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.714 $14.89
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aurinia Pharmaceuticals.

DB:IKAP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:AUP Share Price ÷ EPS (both in USD)

= 14.89 ÷ -1.33

-11.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aurinia Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aurinia Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aurinia Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:IKAP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
61.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aurinia Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aurinia Pharmaceuticals's assets?
Raw Data
DB:IKAP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.45
TSX:AUP Share Price * TSX (2020-04-08) in CAD CA$20.85
TSX:AUP Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.714 $14.89
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:IKAP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:AUP Share Price ÷ Book Value per Share (both in USD)

= 14.89 ÷ 2.45

6.09x

* Primary Listing of Aurinia Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aurinia Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aurinia Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aurinia Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IKAP Future Performance

 How is Aurinia Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aurinia Pharmaceuticals expected to grow at an attractive rate?
  • Aurinia Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Aurinia Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Aurinia Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IKAP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IKAP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 61.7%
DB:IKAP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 54.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IKAP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IKAP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 735 288 336 5
2023-12-31 492 159 181 5
2022-12-31 319 -9 69 5
2021-12-31 98 -85 -77 6
2020-12-31 0 -89 -115 6
2020-04-09
DB:IKAP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -63 -124
2019-09-30 0 -52 -62
2019-06-30 0 -51 -61
2019-03-31 0 -50 -61
2018-12-31 0 -52 -64
2018-09-30 0 -47 -53
2018-06-30 0 -44 -48
2018-03-31 0 -46 -34
2017-12-31 0 -41 -71
2017-09-30 0 -36 -76
2017-06-30 0 -32 -70
2017-03-31 0 -23 -71

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aurinia Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Aurinia Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IKAP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IKAP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.79 4.28 1.45 5.00
2023-12-31 1.49 2.66 0.46 5.00
2022-12-31 0.65 1.88 -0.39 6.00
2021-12-31 -0.97 -0.10 -2.26 6.00
2020-12-31 -1.13 -0.32 -3.34 8.00
2020-04-09
DB:IKAP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.33
2019-09-30 -0.69
2019-06-30 -0.70
2019-03-31 -0.71
2018-12-31 -0.76
2018-09-30 -0.63
2018-06-30 -0.56
2018-03-31 -0.41
2017-12-31 -0.92
2017-09-30 -1.15
2017-06-30 -1.30
2017-03-31 -1.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Aurinia Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Aurinia Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aurinia Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IKAP Past Performance

  How has Aurinia Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aurinia Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aurinia Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aurinia Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aurinia Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aurinia Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IKAP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.32 -123.85 22.15
2019-09-30 0.32 -61.96 18.41
2019-06-30 0.46 -61.26 15.27
2019-03-31 0.46 -61.07 13.78
2018-12-31 0.46 -64.12 13.67
2018-09-30 0.46 -52.86 13.81
2018-06-30 0.12 -47.64 13.54
2018-03-31 0.42 -34.33 12.98
2017-12-31 0.42 -70.79 12.10
2017-09-30 0.42 -75.79 10.69
2017-06-30 0.42 -70.09 9.75
2017-03-31 0.15 -70.97 8.69
2016-12-31 0.17 -23.30 6.97
2016-09-30 0.20 -19.03 6.31
2016-06-30 0.23 -16.82 5.97
2016-03-31 0.23 -14.27 5.55
2015-12-31 0.24 -18.61 6.26
2015-09-30 0.25 -20.90 6.10
2015-06-30 0.26 -12.95 6.12
2015-03-31 0.27 -23.25 6.42
2014-12-31 0.28 -19.42 6.89
2014-09-30 0.92 -14.76 6.31
2014-06-30 0.93 -16.72 5.40
2014-03-31 0.95 -6.65 4.18
2013-12-31 0.97 -2.66 2.30
2013-09-30 0.40 -6.01 2.38
2013-06-30 0.40 -8.29 2.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aurinia Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aurinia Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aurinia Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aurinia Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aurinia Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IKAP Health

 How is Aurinia Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aurinia Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aurinia Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aurinia Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aurinia Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -833.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago.

DB:IKAP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 273.52 0.00 306.02
2019-09-30 123.74 0.00 134.54
2019-06-30 125.87 0.00 131.49
2019-03-31 139.35 0.00 144.33
2018-12-31 112.58 0.00 125.86
2018-09-30 125.34 0.00 138.88
2018-06-30 142.17 0.00 150.20
2018-03-31 152.45 0.00 159.13
2017-12-31 165.74 0.00 173.46
2017-09-30 167.64 0.00 182.41
2017-06-30 178.47 0.00 189.79
2017-03-31 172.66 0.00 202.12
2016-12-31 35.95 0.00 39.65
2016-09-30 20.10 0.00 15.38
2016-06-30 19.54 0.00 12.12
2016-03-31 16.03 0.00 10.53
2015-12-31 19.96 0.00 15.75
2015-09-30 23.54 0.00 20.58
2015-06-30 28.01 0.00 25.74
2015-03-31 27.56 0.00 29.04
2014-12-31 33.87 0.00 32.70
2014-09-30 49.32 0.00 35.53
2014-06-30 51.07 0.00 39.09
2014-03-31 54.62 0.00 43.29
2013-12-31 13.31 1.32 1.82
2013-09-30 12.26 1.69 4.51
2013-06-30 -2.89 0.00 0.45
  • Unable to establish if Aurinia Pharmaceuticals's level of debt is high without past debt data.
  • Unable to establish if Aurinia Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aurinia Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Aurinia Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Aurinia Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aurinia Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IKAP Dividends

 What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aurinia Pharmaceuticals dividends.
If you bought €2,000 of Aurinia Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aurinia Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aurinia Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IKAP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IKAP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aurinia Pharmaceuticals has not reported any payouts.
  • Unable to verify if Aurinia Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aurinia Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aurinia Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aurinia Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aurinia Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aurinia Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IKAP Management

 What is the CEO of Aurinia Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Greenleaf
AGE 49
TENURE AS CEO 1 years
CEO Bio

Mr. Peter S. Greenleaf, M.B.A., has been Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019 and has been its President. He has been a Director at Antares Pharma, Inc. since December 13, 2018. He served as a Director of EyeGate Pharmaceuticals, Inc. since July 10, 2018 until January 3, 2020. He was Chief Executive Officer of Cerecor Inc. since March 28, 2018 until April 15, 2019. He serves as a Member of Advisory Board at Petrichor Healthcare Capital Management LP. He served as the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and since March 03, 2014 until February 2018 respectively. Mr. Greenleaf was an Executive Director at Sucampo Pharmaceuticals, Inc. from March 03, 2014 to February 2018. He served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. From 2006 to 2013, he was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he served as President. He served as President of MedImmune Ventures from January 2010 to June 2013. He served as President of MedImmune Limited since February 2010. He served as the Senior Vice President of marketing and sales of Medimmune Inc., since May 2006 and its Senior Vice President of Commercial Operations, Corporate Development & Strategy and MedImmune Ventures Inc. He served as Chief Commercial Officer of MedImmune. He initially joined MedImmune LLC in 2006 until 2010 as Senior Vice President of Commercial Operations. He held senior commercial roles at Centocor, leading the company's gastroenterology division. He served as the Vice President of the Gastroenterology Franchise Centocor, Inc. He served as a Director of Synlogic, Inc. until August 28, 2017. Mr. Greenleaf joined Centocor's Cardiovascular Division in 1998 and moved into the immunology business, holding a number of postions with increasing responsibility in sales and marketing. He served in sales and marketing capacities at Boehringer Mannheim Corporation and US Healthcare, Inc. He has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. He serves as Chairman of Maryland Venture Fund Authority. He had been a Director of Cerecor Inc. since May 15, 2017 until February 13, 2020. He serves as Chairman of BioDelivery Sciences International, Inc. since May 17, 2018. He previously served on the boards of PhARMA. He has been a Director of Mirna Therapeutics, Inc. since February 1, 2016 to August 2017. He served as Director of Savara Inc. until April 27, 2017. He was a Director of Mast Therapeutics, Inc., since November 2015 to April 2017. He is also a Member of The Board of Directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. He served as Director of Savara Inc. He served as a Director of Corridor Pharmaceuticals, Inc. from 2010 to 2013; Takeda Vaccines (Montana), Inc.; Histogenics Corporation from June 2013 to March 2014; LigoCyte Pharmaceuticals, Inc. from 2010 to 2011; Melinta Therapeutics, Inc., (formerly Rib-X Pharmaceuticals, Inc.) since January 20, 2010 and University of Maryland Baltimore Foundation, Inc. Mr. Greenleaf has an M.B.A. from St. Joseph's University and a B.S. degree from Western Connecticut State University.

CEO Compensation
  • Insufficient data for Peter to compare compensation growth.
  • Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Aurinia Pharmaceuticals management team in years:

2.5
Average Tenure
  • The tenure for the Aurinia Pharmaceuticals management team is about average.
Management Team

Michael Martin

TITLE
Co-Founder & COO
COMPENSATION
$702K

Dennis Bourgeault

TITLE
CFO & Secretary
COMPENSATION
$681K
TENURE
21.9 yrs

Rob Huizinga

TITLE
Executive Vice President of Corporate Development
COMPENSATION
$963K
TENURE
2.9 yrs

Neil Solomons

TITLE
Chief Medical Officer
COMPENSATION
$881K
TENURE
6.6 yrs

Peter Greenleaf

TITLE
President
AGE
49
TENURE
1 yrs

Glenn Schulman

TITLE
Senior Vice President of Corporate Communications & Investor Relations

Erik Eglite

TITLE
Senior VP
AGE
54
TENURE
2.8 yrs

Chris Hays

TITLE
Vice President of Marketing
TENURE
0.2 yrs

Fran Lynch

TITLE
Vice President of Sales
TENURE
0.2 yrs

Rivka Gluck

TITLE
Senior Vice President of Global Clinical Operations
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Aurinia Pharmaceuticals board of directors in years:

1
Average Tenure
64.5
Average Age
  • The average tenure for the Aurinia Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

George Milne

TITLE
Chairman of the Board
COMPENSATION
$127K
AGE
75
TENURE
1 yrs

Peter Greenleaf

TITLE
President
AGE
49
TENURE
1 yrs

Jay Hagan

TITLE
Independent Director
COMPENSATION
$165K
AGE
50
TENURE
2.2 yrs

R. Mackay-Dunn

TITLE
Independent Director
AGE
68
TENURE
0.8 yrs

Jill Leversage

TITLE
Independent Director
AGE
63
TENURE
0.4 yrs

David R. Jayne

TITLE
Non-Executive Director
COMPENSATION
$121K
AGE
62
TENURE
4.9 yrs

Michael Hayden

TITLE
Independent Director
COMPENSATION
$175K
AGE
68
TENURE
2.2 yrs

Daniel Billen

TITLE
Director
AGE
66
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • Aurinia Pharmaceuticals individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Mar 20 Sell Neil Solomons Individual 10. Mar 20 10. Mar 20 -60,700 €13.47 €-817,404
22. Jan 20 Buy R. Mackay-Dunn Individual 22. Jan 20 22. Jan 20 500 €16.97 €8,485
05. Jan 20 Sell Dennis Bourgeault Individual 02. Jan 20 02. Jan 20 -3,000 €19.02 €-57,051
06. Jan 20 Sell Bradley Dickerson Individual 02. Jan 20 02. Jan 20 -50,000 €18.79 €-939,252
20. Dec 19 Buy R. Mackay-Dunn Individual 19. Dec 19 19. Dec 19 1,000 €16.82 €16,770
17. Dec 19 Sell Dennis Bourgeault Individual 12. Dec 19 12. Dec 19 -5,000 €16.74 €-83,724
16. Dec 19 Sell ILJIN SNT Co., Ltd Company 11. Dec 19 11. Dec 19 -200,000 €16.34 €-3,267,825
16. Dec 19 Sell Bradley Dickerson Individual 12. Dec 19 12. Dec 19 -11,000 €16.54 €-181,919
16. Dec 19 Sell Neil Solomons Individual 12. Dec 19 12. Dec 19 -20,000 €16.47 €-329,469
09. Dec 19 Sell ILJIN SNT Co., Ltd Company 06. Dec 19 09. Dec 19 -1,900,000 €14.04 €-26,473,009
06. Dec 19 Sell ILJIN SNT Co., Ltd Company 27. Nov 19 05. Dec 19 -591,567 €15.09 €-8,491,980
26. Nov 19 Sell ILJIN SNT Co., Ltd Company 21. Nov 19 26. Nov 19 -403,892 €6.25 €-2,387,359
21. Oct 19 Buy George Milne Individual 16. Oct 19 16. Oct 19 10,000 €4.48 €44,833
15. Oct 19 Buy Peter Greenleaf Individual 15. Oct 19 15. Oct 19 8,328 €4.17 €34,712
15. Oct 19 Buy Joseph Hagan Individual 11. Oct 19 15. Oct 19 3,500 €4.31 €13,875
14. Oct 19 Buy Bradley Dickerson Individual 14. Oct 19 14. Oct 19 5,000 €3.51 €17,558
10. Oct 19 Buy Rashieda Gluck Individual 10. Oct 19 10. Oct 19 2,000 €2.91 €5,816
02. Oct 19 Buy Bradley Dickerson Individual 30. Sep 19 30. Sep 19 3,000 €4.94 €14,830
26. Sep 19 Buy Stephen Robertson Individual 26. Sep 19 26. Sep 19 1,050 €5.13 €5,384
08. Jul 19 Buy George Milne Individual 08. Jul 19 08. Jul 19 10,000 €5.64 €56,356
03. Jul 19 Sell Rashieda Gluck Individual 01. Jul 19 01. Jul 19 -1,483 €5.82 €-8,637
01. Jul 19 Buy Bradley Dickerson Individual 01. Jul 19 01. Jul 19 2,000 €5.83 €11,666
26. Apr 19 Sell Neil Solomons Individual 23. Apr 19 25. Apr 19 -44,733 €5.70 €-252,175
X
Management checks
We assess Aurinia Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aurinia Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IKAP News

Simply Wall St News

IKAP Company Info

Description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Details
Name: Aurinia Pharmaceuticals Inc.
IKAP
Exchange: DB
Founded:
CA$1,537,887,994
112,297,331
Website: http://www.auriniapharma.com
Address: Aurinia Pharmaceuticals Inc.
4464 Markham Street,
Suite 1203,
Victoria,
British Columbia, V8Z 7X8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX AUP Common Shares The Toronto Stock Exchange CA CAD 26. Jan 1999
NasdaqGM AUPH Common Shares Nasdaq Global Market US USD 26. Jan 1999
DB IKAP Common Shares Deutsche Boerse AG DE EUR 26. Jan 1999
LSE 0UJF Common Shares London Stock Exchange GB CAD 26. Jan 1999
Number of employees
Current staff
Staff numbers
62
Aurinia Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:21
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.